Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib Adjuvant Therapy in Early HNSCC and NSCLC
NCT00527982Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2005
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of celecoxib oral solution in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Histological Response (Ki-67, apoptosis). Started Sep 2005; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00527982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527982.